+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Natural Killer Cells Therapeutics Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • PDF Icon

    Report

  • 138 Pages
  • November 2023
  • Region: Global
  • IMARC Group
  • ID: 5912139
The global natural killer cells therapeutics market size reached US$ 2.5 Billion in 2022. Looking forward, the market is expected to reach US$ 5.4 Billion by 2028, exhibiting a growth rate (CAGR) of 13.70% during 2022-2028.

Natural killer (NK) cells therapeutics target multiple pathogenic antigens with efficient cytotoxicity and reduce the risk of cytokine storms. They can be produced from a variety of sources without relying on patient-specific immune cells. At present, several strategies have been developed, such as ex vivo pre-conditioning with cytokines or small molecular drugs and engineering a chimeric antigen receptor (CAR) NK, which improve the efficacy of NK cells therapeutics. Moreover, researchers are focusing on maximizing the therapeutic effects of allogeneic NK cells through robust expansion, enhanced targeting, and extended persistence of potent immune cells. This can also help unleash a strong and sustained anti-cancer immune-mediated attack.

Natural Killer Cells Therapeutics Market Trends

A significant rise in the number of individuals with cancer, infectious diseases, and liver disorders represents one of the primary factors fueling the market growth. This can be attributed to unhealthy dietary patterns, lack of physical activities, growing air pollution, and the increasing number of individuals consuming alcohol and tobacco products. Moreover, as the risk of developing cancer rises dramatically with age, the increasing geriatric population across the globe is acting as another growth-inducing factor catalyzing the demand for NK cells therapeutics. Apart from this, as the immune response of cancer patients is not adequate, health companies are developing novel methods and technologies to boost the immune response through allogeneic, off-the-shelf NK cell-based therapies. Furthermore, there is a rise in the number of clinical studies that focus on tumor-targeted antibody strategies to enhance the therapeutic benefit of NK-cell-based therapy while minimizing risks and toxicities. In addition, governing agencies of numerous countries are funding financial schemes for cancer patients, which is creating a favorable outlook for the market.

Key Market Segmentation

This research provides an analysis of the key trends in each sub-segment of the global natural killer cells therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. The report has categorized the market based on therapeutics, application and end user.

Breakup by Therapeutics:

  • NK Cell Therapies
  • NK Cell Directed Antibodies

Breakup by Application:

  • Cancer
  • Gastrointestinal Diseases
  • Immunoproliferative Disorders

Breakup by End User:

  • Hospitals
  • Research Centers and Institutes

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Latin America
  • Brazil
  • Mexico
  • Middle East and Africa

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players being Affimed GmbH, Bristol-Myers Squibb Company, Fate Therapeutics, Fortress Biotech Inc., Glycostem Therapeutics, Innate Pharma S.A., Kuur Therapeutics Inc. (Athenex Inc.), Nkarta Inc., Takeda Pharmaceutical Company Limited and Ziopharm Oncology Inc.

Key Questions Answered in This Report

1. What was the size of the global natural killer cells therapeutics market in 2022?
2. What is the expected growth rate of the global natural killer cells therapeutics market during 2023-2028?
3. What are the key factors driving the global natural killer cells therapeutics market?
4. What has been the impact of COVID-19 on the global natural killer cells therapeutics market?
5. What is the breakup of the global natural killer cells therapeutics market based on the therapeutics?
6. What is the breakup of the global natural killer cells therapeutics market based on the application?
7. What is the breakup of the global natural killer cells therapeutics market based on the end user?
8. What are the key regions in the global natural killer cells therapeutics market?
9. Who are the key players/companies in the global natural killer cells therapeutics market?

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Natural Killer Cells Therapeutics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Therapeutics
6.1 NK Cell Therapies
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 NK Cell Directed Antibodies
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Application
7.1 Cancer
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Gastrointestinal Diseases
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Immunoproliferative Disorders
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Research Centers and Institutes
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Affimed GmbH
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Bristol-Myers Squibb Company
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Fate Therapeutics
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.4 Fortress Biotech Inc.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Glycostem Therapeutics
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 Innate Pharma S.A.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.7 Kuur Therapeutics Inc. (Athenex Inc.)
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.8 Nkarta Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.9 Takeda Pharmaceutical Company Limited
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Ziopharm Oncology Inc.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials

Companies Mentioned

  • Affimed GmbH
  • Bristol-Myers Squibb Company
  • Fate Therapeutics
  • Fortress Biotech Inc.
  • Glycostem Therapeutics
  • Innate Pharma S.A.
  • Kuur Therapeutics Inc. (Athenex Inc.)
  • Nkarta Inc.
  • Takeda Pharmaceutical Company Limited
  • Ziopharm Oncology Inc.

Methodology

Loading
LOADING...

Table Information